MX374342B - Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes. - Google Patents

Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes.

Info

Publication number
MX374342B
MX374342B MX2016015176A MX2016015176A MX374342B MX 374342 B MX374342 B MX 374342B MX 2016015176 A MX2016015176 A MX 2016015176A MX 2016015176 A MX2016015176 A MX 2016015176A MX 374342 B MX374342 B MX 374342B
Authority
MX
Mexico
Prior art keywords
cancer
site
drug conjugates
adc
antibodies
Prior art date
Application number
MX2016015176A
Other languages
English (en)
Other versions
MX2016015176A (es
Inventor
Gerardus Joseph Andreas Ariaans
Rudy Gerardus Elisabeth Coumans
Original Assignee
Byondis Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX374342(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byondis Bv filed Critical Byondis Bv
Publication of MX2016015176A publication Critical patent/MX2016015176A/es
Publication of MX374342B publication Critical patent/MX374342B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a conjugados de fármaco-anticuerpo (ADC), en donde un fármaco enlazador está conjugado con un anticuerpo de manera específica de sitio, por medio de una cisteína construida, y a su uso como medicamento, particularmente para el tratamiento de tumores sólidos y malignidades hematológicas humanas, en particular cáncer de mama, cáncer gástrico, cáncer colorrectal, cáncer urotelial, cáncer de ovario, cáncer uterino, cáncer de pulmón, mesotelioma, cáncer de hígado, cáncer pancreático, cáncer de próstata y leucemia.
MX2016015176A 2014-05-22 2015-05-22 Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes. MX374342B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169493 2014-05-22
PCT/EP2015/061456 WO2015177360A1 (en) 2014-05-22 2015-05-22 Site-specific conjugation of linker drugs to antibodies and resulting adcs

Publications (2)

Publication Number Publication Date
MX2016015176A MX2016015176A (es) 2017-03-23
MX374342B true MX374342B (es) 2025-03-06

Family

ID=50771151

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015030A MX393934B (es) 2014-05-22 2015-05-22 Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes
MX2016015176A MX374342B (es) 2014-05-22 2015-05-22 Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019015030A MX393934B (es) 2014-05-22 2015-05-22 Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes

Country Status (22)

Country Link
US (4) US10407743B2 (es)
EP (3) EP3539544A1 (es)
JP (2) JP6517240B2 (es)
KR (1) KR102419766B1 (es)
CN (1) CN106456794B (es)
AU (2) AU2015261768B2 (es)
CA (1) CA2947238A1 (es)
CL (1) CL2016002941A1 (es)
CY (1) CY1125232T1 (es)
DK (1) DK3151865T3 (es)
ES (1) ES2895623T3 (es)
HR (1) HRP20211710T1 (es)
HU (1) HUE056023T2 (es)
LT (1) LT3151865T (es)
MX (2) MX393934B (es)
MY (1) MY183480A (es)
PL (1) PL3151865T3 (es)
PT (1) PT3151865T (es)
RU (1) RU2670157C2 (es)
SG (2) SG10201913977TA (es)
WO (1) WO2015177360A1 (es)
ZA (1) ZA201607109B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
HUE030846T2 (en) 2010-04-21 2017-06-28 Syntarga Bv Conjugates of cc-1065 analogs and bifunctional linkers
EP2948184B1 (en) 2014-01-10 2016-03-23 Synthon Biopharmaceuticals B.V. Duocarmycin adcs showing improved in vivo antitumor activity
RU2686085C2 (ru) 2014-01-10 2019-04-24 Синтон Байофармасьютикалс Б. В. Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия
KR102419766B1 (ko) * 2014-05-22 2022-07-13 비온디스 비.브이. 항체에 대한 링커 약물의 부위 특이적 접합 및 그 결과로 얻어지는 adc
LT3152191T (lt) 2014-06-05 2019-08-26 Synthon Biopharmaceuticals B.V. Pagerintas duokarmicino provaistų gavimo būdas
TWI744261B (zh) * 2015-11-24 2021-11-01 荷蘭商拜恩迪斯公司 抗５ｔ４抗體和抗體-藥物共軛體
CN110606890B (zh) * 2015-12-24 2021-11-26 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
CN108883196A (zh) * 2016-02-05 2018-11-23 米伦纽姆医药公司 靶向gcc的抗体－药物缀合物
EP3458100B1 (en) * 2016-02-12 2020-07-01 Byondis B.V Selective reduction of cysteine-engineered antibodies
EP3464379B1 (en) 2016-06-06 2023-09-27 Abzena (UK) Limited Antibodies, uses thereof and conjugates thereof
TWI750194B (zh) * 2016-07-05 2021-12-21 大陸商江蘇恆瑞醫藥股份有限公司 Ｅｇｆｒ抗體-藥物偶聯物及其在醫藥上的應用
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
EP3525826B1 (en) * 2016-10-11 2020-07-22 Byondis B.V Non-linear self-immolative linkers and conjugates thereof
ES2853999T3 (es) 2016-11-14 2021-09-20 Byondis Bv Proceso para la preparación de alpha, omega-diamino alcanos mono-protegidos
US11779642B2 (en) 2016-12-09 2023-10-10 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
CN108285487B (zh) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
JP7284707B2 (ja) 2017-04-07 2023-05-31 ジュノー セラピューティクス インコーポレイテッド 前立腺特異的膜抗原（ｐｓｍａ）またはその改変型を発現する操作された細胞および関連方法
WO2018215427A1 (en) 2017-05-23 2018-11-29 Synthon Biopharmaceuticals B.V. Dual conjugation process for preparing antibody-drug conjugates
US20200129633A1 (en) * 2017-06-06 2020-04-30 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof
JP2020523319A (ja) * 2017-06-07 2020-08-06 シルバーバック セラピューティックス インコーポレイテッド 免疫調節化合物の抗体コンジュゲートおよびその使用
CN110869394A (zh) * 2017-06-16 2020-03-06 伊莱利利公司 工程改造的抗体化合物及其缀合物
WO2019046859A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF
EP3678682A4 (en) * 2017-09-06 2021-06-09 Airway Therapeutics, Inc. METHOD, COMPOSITIONS AND CELLS FOR MANUFACTURING SURFACTANT PROTEIN D (SP-D)
CA3074280A1 (en) 2017-09-06 2019-03-14 Airway Therapeutics, LLC Methods and compositions for preparing surfactant protein d (sp-d)
DK3713939T3 (da) 2017-11-24 2021-09-13 Byondis Bv Forbedret fremgangsmåde til syntese af linker-lægemidlet vc-seco
EP3717069A1 (en) * 2017-11-27 2020-10-07 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
HRP20231280T1 (hr) 2018-03-13 2024-02-02 Zymeworks Bc Inc. Anti-her2 biparatopski antitijelo-konjugati lijeka i načini uporabe
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
AU2019240403A1 (en) * 2018-03-23 2020-10-08 Seagen Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
WO2019189453A1 (en) 2018-03-28 2019-10-03 Mitsubishi Tanabe Pharma Corporation DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
CN112739716B (zh) 2018-05-07 2025-05-27 展马博联合股份有限公司 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
JP7337099B2 (ja) 2018-05-25 2023-09-01 アレクトル エルエルシー 抗ｓｉｒｐａ抗体およびその使用法
MX2021001058A (es) * 2018-08-16 2021-04-12 Genmab As Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer.
KR102520974B1 (ko) * 2018-08-29 2023-04-17 레메젠 코, 리미티드 요로상피 암종의 치료에서 항―ｈｅｒ２ 항체―약물 접합체의 용도
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US20210393791A1 (en) * 2018-10-31 2021-12-23 Health Research, Inc. Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor
PT3876997T (pt) * 2018-11-09 2022-11-11 Byondis Bv Composições de conjugados anticorpo-fármaco contendo duocarmicina filtrável e métodos relacionados
WO2020181846A1 (zh) * 2019-03-11 2020-09-17 凯惠科技发展(上海)有限公司 一种含半胱氨酸的抗体、药物偶联物及其应用
CA3154710A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
MX2022009696A (es) 2020-02-06 2022-09-07 Byondis Bv Combinacion que contiene un conjugado de anticuerpo-farmaco que comprende derivado de duocarmicina y tiosulfato.
IL299184A (en) 2020-07-06 2023-02-01 Byondis Bv Anti-folic acid drugs and antibody-conjugated drugs
CN116761824B (zh) * 2021-01-18 2024-06-21 上海药明合联生物技术有限公司 工程化抗-trop2抗体及其抗体-药物偶联物
WO2022214517A1 (en) 2021-04-08 2022-10-13 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
US20240261426A1 (en) 2021-06-28 2024-08-08 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy
CN114106180B (zh) * 2021-12-13 2023-07-28 中国药科大学 一种单克隆抗体及其应用
AU2022425491A1 (en) 2021-12-30 2024-07-04 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
US20250136717A1 (en) 2022-05-16 2025-05-01 Byondis B.V. Novel masked antibodies
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2024133374A1 (en) 2022-12-22 2024-06-27 Byondis B.V. Novel linker drugs comprising phosphoantigens, novel conjugates and their use in therapy
TW202444424A (zh) * 2023-03-22 2024-11-16 美商艾克塞里克斯公司 Dll3抗體-藥物結合物及其用途
CN116212045A (zh) * 2023-03-31 2023-06-06 温州医科大学 靶向癌细胞表面muc1的新型抗体药物偶联物及其制备方法与应用
WO2024258743A1 (en) 2023-06-13 2024-12-19 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
GB202312576D0 (en) * 2023-08-17 2023-10-04 Bivictrix Ltd A compound comprising a first and second antibody or antigen-binding fragment and methods of conjugating the same
US20250177547A1 (en) * 2023-11-30 2025-06-05 Abbvie Inc. PSMA-STEAP1 DUAL VARIABLE DOMAIN IMMUNOGLOBLIN (DVD-Ig) MOLECULES AND DRUG CONJUGATES
WO2025155626A1 (en) * 2024-01-16 2025-07-24 Obi Pharma, Inc. Method for antibody-drug conjugate quality improvement
WO2025211773A1 (ko) * 2024-04-02 2025-10-09 주식회사 지놈앤컴퍼니 항-cntn4 항체를 포함하는 컨쥬게이트 및 이의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
AU2005218642B2 (en) 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
GT200500255A (es) 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
KR20150126978A (ko) 2005-06-20 2015-11-13 피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 Ｐｓｍａ 항체-약물 접합체
ES2416136T3 (es) * 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
AU2007226696C1 (en) 2006-03-10 2016-02-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
HRP20140172T1 (hr) * 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
US8680293B2 (en) 2007-08-01 2014-03-25 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
HUE035798T2 (en) 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
WO2011069019A2 (en) * 2009-12-02 2011-06-09 David Ho J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
HUE030846T2 (en) 2010-04-21 2017-06-28 Syntarga Bv Conjugates of cc-1065 analogs and bifunctional linkers
PL2694111T3 (pl) * 2011-04-01 2017-01-31 Wyeth Llc Koniugaty przeciwciało-lek
CA2859755C (en) * 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2906250B1 (en) * 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
SI2953976T1 (sl) 2013-02-08 2021-08-31 Novartis Ag Specifična mesta z modificiranje protiteles za izdelavo imunokonjugatov
RU2686085C2 (ru) 2014-01-10 2019-04-24 Синтон Байофармасьютикалс Б. В. Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия
LT3092010T (lt) 2014-01-10 2018-10-25 Synthon Biopharmaceuticals B.V. Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų
EP2948184B1 (en) 2014-01-10 2016-03-23 Synthon Biopharmaceuticals B.V. Duocarmycin adcs showing improved in vivo antitumor activity
KR102419766B1 (ko) * 2014-05-22 2022-07-13 비온디스 비.브이. 항체에 대한 링커 약물의 부위 특이적 접합 및 그 결과로 얻어지는 adc
LT3152191T (lt) 2014-06-05 2019-08-26 Synthon Biopharmaceuticals B.V. Pagerintas duokarmicino provaistų gavimo būdas
US20170320965A1 (en) 2014-09-22 2017-11-09 Synthon Biopharmaceuticals B.V. Pan-reactive antibodies to duocarmycins
TWI744261B (zh) * 2015-11-24 2021-11-01 荷蘭商拜恩迪斯公司 抗５ｔ４抗體和抗體-藥物共軛體

Also Published As

Publication number Publication date
CA2947238A1 (en) 2015-11-26
SG11201609372UA (en) 2016-12-29
CL2016002941A1 (es) 2017-12-22
EP3151865A1 (en) 2017-04-12
ES2895623T3 (es) 2022-02-22
HRP20211710T1 (hr) 2022-02-04
RU2016150377A3 (es) 2018-06-25
MY183480A (en) 2021-02-19
US11104968B2 (en) 2021-08-31
WO2015177360A1 (en) 2015-11-26
US20170080103A1 (en) 2017-03-23
PL3151865T3 (pl) 2022-01-03
US20190367999A1 (en) 2019-12-05
DK3151865T3 (da) 2021-10-25
AU2020200175A1 (en) 2020-01-30
BR112016026744A2 (pt) 2017-12-12
JP6517240B2 (ja) 2019-05-22
RU2016150377A (ru) 2018-06-25
EP3539544A1 (en) 2019-09-18
KR20170005128A (ko) 2017-01-11
LT3151865T (lt) 2021-10-25
AU2015261768A1 (en) 2016-11-03
CN106456794B (zh) 2023-02-17
ZA201607109B (en) 2018-05-30
PT3151865T (pt) 2021-11-17
JP6900408B2 (ja) 2021-07-07
EP3151865B1 (en) 2021-09-01
JP2019089783A (ja) 2019-06-13
US10407743B2 (en) 2019-09-10
US12180552B2 (en) 2024-12-31
US20210388115A1 (en) 2021-12-16
SG10201913977TA (en) 2020-03-30
MX393934B (es) 2025-03-24
RU2018133015A3 (es) 2021-12-07
MX2016015176A (es) 2017-03-23
US11136633B2 (en) 2021-10-05
JP2017524653A (ja) 2017-08-31
US20190368000A1 (en) 2019-12-05
EP3868379A1 (en) 2021-08-25
AU2015261768B2 (en) 2020-03-26
RU2018133015A (ru) 2018-12-04
CY1125232T1 (el) 2023-03-24
HUE056023T2 (hu) 2022-01-28
RU2670157C2 (ru) 2018-10-18
CN106456794A (zh) 2017-02-22
KR102419766B1 (ko) 2022-07-13
AU2020200175B2 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
MX374342B (es) Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
NZ710929A (en) Antibody drug conjugates
ZA201805853B (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
CL2016000465A1 (es) Métodos de conjugación de anticuerpos específicos de sitio y composiciones.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
PH12014501039B1 (en) Cytotoxic peptides and antibody drug conjugates thereof
ECSP19044625A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
SG10202105348WA (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: KONECRANES GLOBAL CORPORATION